Gerald Massonnet
Overview
Explore the profile of Gerald Massonnet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
345
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Decaudin D, El Botty R, Diallo B, Massonnet G, Fleury J, Naguez A, et al.
Oncotarget
. 2018 May;
9(31):21674-21686.
PMID: 29774094
The prognosis of metastatic uveal melanoma (UM) is among the worst of all human cancers. The identification of near-ubiquitous GNAQ/GNA11 mutations and the activation of MAPK signaling in UM have...
2.
Bougherara H, Nemati F, Nicolas A, Massonnet G, Pugniere M, Ngo C, et al.
Oncotarget
. 2017 Dec;
8(59):99950-99965.
PMID: 29245952
Müllerian inhibiting substance, also called anti-Müllerian hormone (AMH), inhibits proliferation and induces apoptosis of AMH type II receptor-positive tumor cells, such as human ovarian cancers (OCs). On this basis, a...
3.
Crepin R, Gentien D, Duche A, Rapinat A, Reyes C, Nemati F, et al.
Pigment Cell Melanoma Res
. 2017 Feb;
30(3):317-327.
PMID: 28140525
Monoclonal antibodies specific for biomarkers expressed on the surface of uveal melanoma (UM) cells would simplify the immune capture and genomic characterization of heterogeneous tumor cells originated from patient-derived xenografts...
4.
Vallerand D, Massonnet G, Kebir F, Gentien D, Maciorowski Z, De La Grange P, et al.
PLoS One
. 2016 Jul;
11(7):e0157670.
PMID: 27388901
Drug discovery efforts have focused on the tumor microenvironment in recent years. However, few studies have characterized the stroma component in patient-derived xenografts (PDXs) and genetically engineered mouse models (GEMs)....
5.
Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, et al.
Nature
. 2015 Sep;
525(7569):380-3.
PMID: 26331539
Whether cancer is maintained by a small number of stem cells or is composed of proliferating cells with approximate phenotypic equivalency is a central question in cancer biology. In the...
6.
Nunes M, Vrignaud P, Vacher S, Richon S, Lievre A, Cacheux W, et al.
Cancer Res
. 2015 Feb;
75(8):1560-6.
PMID: 25712343
Development of targeted therapeutics required translationally relevant preclinical models with well-characterized cancer genome alterations. Here, by studying 52 colorectal patient-derived tumor xenografts (PDX), we examined key molecular alterations of the...
7.
Stimmer L, Dehay S, Nemati F, Massonnet G, Richon S, Decaudin D, et al.
BMC Cancer
. 2014 Dec;
14:916.
PMID: 25476116
Background: The B-subunit of Shiga toxin (STxB) specifically binds to the glycosphingolipid Gb3 that is highly expressed on a number of human tumors and has been shown to target tumor...
8.
Petit V, Massonnet G, Maciorowski Z, Touhami J, Thuleau A, Nemati F, et al.
Lab Invest
. 2013 Mar;
93(5):611-21.
PMID: 23459372
Metabolic adaptations and changes in the expression of nutrient transporters are known to accompany tumorigenic processes. Nevertheless, in the context of solid tumors, studies of metabolism are hindered by a...
9.
Kiladjian J, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, et al.
Blood
. 2006 May;
108(6):2037-40.
PMID: 16709929
V617F JAK2 mutation is a reliable molecular marker of polycythemia vera (PV), potentially useful to monitor the effect of treatments in this disease. In a phase 2 study of pegylated...